IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer

Scientists observed that interleukin-1 receptor type 2 (IL1R2) blockade strongly attenuated macrophage recruitment and the polarization of tumor-associated macrophages to inhibit breast tumor-initiating cell (BTIC) self-renewal and CD8+ T cell exhaustion, which resulted in reduced tumor burden and prolonged survival in TNBC mouse models.